3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Breast
1
Conditions
Brain Neoplasms
19
Breast Neoplasms
14
Glioblastoma
4
Squamous Cell Carcinoma of Head and Neck
3
Salivary Gland Neoplasms
3
Neoplasm Metastasis
3
Esthesioneuroblastoma, Olfactory
3
Stomach Neoplasms
2
Neoplasms
2
Meningeal Neoplasms
2
Meningeal Carcinomatosis
2
Head and Neck Neoplasms
2
Glioma
2
Esophageal Neoplasms
2
Carcinoma, Hepatocellular
2
Breast Neoplasms, Male
2
Bile Duct Neoplasms
2
Astrocytoma
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Neoplasms, Unknown Primary
1
Liver Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Appendiceal Neoplasms
1
Interventions
Pemetrexed
20
Bevacizumab
10
Radiotherapy
8
Spinal Puncture
7
osimertinib
6
Methotrexate
6
Magnetic Resonance Spectroscopy
6
aflutinib
5
Topotecan
5
Specimen Handling
5
Trastuzumab
4
Temozolomide
4
Radiotherapy, Intensity-Modulated
4
Dexamethasone
3
trastuzumab deruxtecan
2
pembrolizumab
2
paclitaxel-Angiopep-2 conjugate
2
omburtamab I-131
2
merphos
2
lorlatinib
2
aumolertinib
2
WP 744
2
Vitamin B 12
2
Rituximab
2
Radiation
2
Folic Acid
2
Drug Therapy
2
Cytarabine
2
Cyclophosphamide
2
Capecitabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Meningeal Carcinomatosis
×
Capecitabine
×
CNS
×
Clear all
NCT05800275
2025-11-18
ETIC-LM
UNICANCER
Phase 2
Recruiting
30 enrolled
NCT03613181
2023-04-24
ANGLeD
Angiochem Inc
Phase 3
Unknown
150 enrolled